Leo Niskanen

31.0k citations

347 papers · 22.9k indexed · 7 hit papers · h-index 78

Endocrinology, Diabetes and Metabolism top 0.05%
Physiology top 0.2%
Cardiology and Cardiovascular Medicine top 0.2%
Surgery top 0.5%
Molecular Biology top 2%

Co-authors: Matti Uusitupa David E. Laaksonen Jukka T. Salonen Markku Laakso Timo A. Lakka Kari Punnonen Kristiina Nyyssönen Rainer Rauramaa
Topics: Diabetes, Cardiovascular Risks, and Lipoproteins (44 papers)Diabetes Management and Research (41 papers)Diabetes Treatment and Management (38 papers)
Cited by: Endocrinology, Diabetes and Metabolism Nephrology Cardiology and Cardiovascular Medicine
Journals: New England Journal of Medicine The Lancet JAMA
Partner nations: Finland United States Sweden

In The Last Decade

Leo Niskanen

334 papers receiving 21.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1999 1.5k citations Leo Niskanen et al. profile →
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

2009 872 citations Arne Astrup, Stephan Rössner et al. profile →
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)

2009 856 citations Leo Niskanen, Jari Haukka et al. profile →
Testosterone and Sex Hormone–Binding Globulin Predict the Metabolic Syndrome and Diabetes in Middle-Aged Men

2004 711 citations Leo Niskanen, Tomi‐Pekka Tuomainen et al. profile →
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

2013 606 citations Lawrence A. Leiter, Leo Niskanen et al. profile →
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

2011 536 citations Arne Astrup, Raffaele Carraro et al. profile →
Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged Men

2004 529 citations Leo Niskanen et al. profile →

Peers

Countries citing papers authored by Leo Niskanen

Since Specialization

Citations

This map shows the geographic impact of Leo Niskanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo Niskanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo Niskanen more than expected).

Fields of papers citing papers by Leo Niskanen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leo Niskanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo Niskanen. The network helps show where Leo Niskanen may publish in the future.

Co-authorship network of co-authors of Leo Niskanen

This figure shows the co-authorship network connecting the top 25 collaborators of Leo Niskanen. A scholar is included among the top collaborators of Leo Niskanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo Niskanen. Leo Niskanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Renal Hyperfiltration as a New Mechanism of Smoking-Related Mortality 2024 ·Nicotine & Tobacco Research ·(unknown),Leo Niskanen,Tomi‐Pekka Tuomainen,(unknown)	0
2	Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure – STONE HF) 2023 ·Primary care diabetes ·Kaj Metsärinne,Mikko Pietilä,Ilkka Kantola,Lotta K. Stenman,(unknown),Lasse Ruokolainen,Leo Niskanen	2
3	The association between renal hyperfiltration and mortality is not mediated by diabetes mellitus 2023 ·International Urology and Nephrology ·(unknown),Ari Voutilainen,Leo Niskanen,Tomi‐Pekka Tuomainen	2
4	Mortality-based definition of renal hyperfiltration in middle-aged men: a 35-year cohort from Finland 2021 ·International Urology and Nephrology ·(unknown),Salah Eddine Oussama Kacimi,Leo Niskanen,Tomi‐Pekka Tuomainen	5
5	The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF) 2021 ·Primary care diabetes ·Kaj Metsärinne,Mikko Pietilä,Ilkka Kantola,Lotta K. Stenman,(unknown),(unknown),Tuija Poussa,Leo Niskanen	4
6	Negative interaction of fatty liver and hypertension on cardiovascular mortality in non-diabetic men: 34 years of follow-up 2021 ·Scandinavian Journal of Gastroenterology ·(unknown),Ari Voutilainen,(unknown),Leo Niskanen,Tomi‐Pekka Tuomainen	1
7	Follicle-stimulating hormone is associated with lipids in postmenopausal women 2018 ·Menopause The Journal of The North American Menopause Society ·(unknown),Tomi‐Pekka Tuomainen,Jyrki K. Virtanen,Sarah Witkowski,Leo Niskanen,Elizabeth R. Bertone‐Johnson	26
8	Association of follicle-stimulating hormone levels and risk of type 2 diabetes in older postmenopausal women 2017 ·Menopause The Journal of The North American Menopause Society ·Elizabeth R. Bertone‐Johnson,Jyrki K. Virtanen,Leo Niskanen,Tarja Nurmi,Kimmo Ronkainen,Sari Voutilainen,Jaakko Mursu,Jussi Kauhanen,Tomi‐Pekka Tuomainen	24
9	Kansallisen rekisteritutkimuksen lupamenettelyn sujuvuus - esimerkkinä diabeteksen Käypä hoito -suosituksen toteutuminen 2014 ·(unknown),(unknown),Raija Sipilä,Miika Linna,(unknown),Tatu A. Miettinen,Elli Leppä,Jari Haukka,Jaakko Tuomilehto,Hannes Enlund,Leo Niskanen,Pasi K. Korhonen	0
10	Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial 2012 ·European Journal of Endocrinology ·Leo Niskanen,Lawrence A. Leiter,Edward Franek,Jianping Weng,Taner Damcı,Manuel Muñoz‐Torres,(unknown),Lars Endahl,Trine Vang Skjøth,Allan Vaag	47
11	Perceived need to increase physical activity levels among adults at high risk of type 2 diabetes. A cross-sectional analysis within a community-based diabetes prevention project FIN-D2D 2012 ·BMC Public Health ·(unknown),(unknown),Jari Villberg,Pauli Rintala,Mauno Vanhala,Timo Saaristo,Markku Peltonen,Sirkka Keinänen‐Kiukaanniemi,Eeva Korpi-Hyövälti,Urho M. Kujala,Leena Moilanen,Leo Niskanen,Heikki Oksa,Marita Poskiparta	16
12	Ylipainon ja lihavuuden esiintyvyys tyypin 2 diabetespotilailla 2012 ·Pia Pajunen,Sirkka Keinänen‐Kiukaanniemi,Eeva Korpi-Hyövälti,Satu Männistö,Leo Niskanen,Heikki Oksa,Timo Saaristo,Juha Saltevo,Jouko Sundvall,Mauno Vanhala,Matti Uusitupa,Johan G. Eriksson,Markku Peltonen	1
13	Serum adipokine levels in adults with a history of childhood maltreatment 2012 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Soili M. Lehto,Antti-Pekka Elomaa,Leo Niskanen,Karl‐Heinz Herzig,Tommi Tolmunen,Heimo Viinamäki,Heli Koivumaa‐Honkanen,Anne Huotari,Kirsi Honkalampi,Minna Valkonen‐Korhonen,Sanna Sinikallio,Heli Ruotsalainen,Jukka Hintikka	19
14	Tolerability and weight loss effects of liraglutide in obese adults: a 104-week randomised trial 2009 ·UCL Discovery (University College London) ·Arne Astrup,(unknown),Raffaele Carraro,Nick Finer,Helle Bøggild Hartvig,Marie Kunešová,Michael E. J. Lean,Leo Niskanen,(unknown),A Rissanen	0
15	Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial 2009 ·UCL Discovery (University College London) ·Nick Finer,(unknown),Arne Astrup,Alex Harper,MEJ Lean,Leo Niskanen,(unknown),A Rissanen,Stephan Rössner,L. Van Gaal,(unknown)	1
16	Treatment with Liraglutide, a Once-Daily Human GLP-1 Analog, for 52 Weeks Reduces Weight and Waist Circumference: A Randomized Placebo-Controlled Trial 2009 ·UCL Discovery (University College London) ·Arne Astrup,(unknown),(unknown),(unknown),Nick Finer,(unknown),(unknown),Leo Niskanen,(unknown),A. Rissanen,S Rössner	1
17	[Fabry's disease, recommendation for diagnostics, follow up and treatment in Finland]. 2004 ·PubMed ·Maila Penttinen,Ilkka Kantola,Pirjo Nuutila,Aki Hietaharju,Eero Honkanen,Ilkka Kaitila,Leo Niskanen,Markku J. Savolainen,Jorma Viikari	2
18	2003 William J. Stickel Silver Award. Skin temperatures as a one-time screening tool do not predict future diabetic foot complications 2003 ·UCL Discovery (University College London) ·(unknown),Raffaele Carraro,Nick Finer,(unknown),Marie Kunešová,MEJ Lean,Leo Niskanen,(unknown),(unknown),S Rössner	2
19	Occurrence and predictors of retinopathy and visual acuity in type 2 diabetic patients and control subjects 10-year follow-up from the diagnosis 2002 ·Clinical Diabetology ·(unknown),Markku Teräsvirta,Matti Uusitupa,Leo Niskanen	4
20	COMPARISON OF INTRAVENOUS ENPROFYLLINE AND THEOPHYLLINE IN THE TREATMENT OF ACUTE ASTHMA 1989 ·Current Therapeutic Research ·H. Riska,H Tukiainen,Matti Uusitupa,L. Tammilehto,A. Hakulinen,(unknown),Leo Niskanen,(unknown),(unknown)	1

About Leo Niskanen

Leo Niskanen is a scholar working on Endocrinology, Diabetes and Metabolism, Biological Psychiatry and Behavioral Neuroscience, having authored 347 papers that have together received 22.9k indexed citations. Recurring topics across this work include Diabetes, Cardiovascular Risks, and Lipoproteins (44 papers), Diabetes Management and Research (41 papers) and Diabetes Treatment and Management (38 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (9.4k citations), Nephrology (1.7k citations) and Cardiology and Cardiovascular Medicine (4.5k citations). Leo Niskanen has collaborated with scholars based in Finland, United States and Sweden. Frequent co-authors include Matti Uusitupa, David E. Laaksonen, Jukka T. Salonen, Markku Laakso, Timo A. Lakka, Kari Punnonen, Kristiina Nyyssönen, Rainer Rauramaa, Onni Siitonen and Heimo Viinamäki. Their work appears in journals such as New England Journal of Medicine, The Lancet and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact